Mast Cell Degranulation and Fibroblast Activation in the Morphine-induced Spinal Mass: Role of Mas-related G Protein-coupled Receptor Signaling.


Journal

Anesthesiology
ISSN: 1528-1175
Titre abrégé: Anesthesiology
Pays: United States
ID NLM: 1300217

Informations de publication

Date de publication:
07 2019
Historique:
entrez: 22 6 2019
pubmed: 22 6 2019
medline: 4 1 2020
Statut: ppublish

Résumé

As the meningeally derived, fibroblast-rich, mass-produced by intrathecal morphine infusion is not produced by all opiates, but reduced by mast cell stabilizers, the authors hypothesized a role for meningeal mast cell/fibroblast activation. Using the guinea pig, the authors asked: (1) Are intrathecal morphine masses blocked by opiate antagonism?; (2) Do opioid agonists not producing mast cell degranulation or fibroblast activation produce masses?; and (3) Do masses covary with Mas-related G protein-coupled receptor signaling thought to mediate mast cell degranulation? In adult male guinea pigs (N = 66), lumbar intrathecal catheters connected to osmotic minipumps (14 days; 0.5 µl/h) were placed to deliver saline or equianalgesic concentrations of morphine sulfate (33 nmol/h), 2',6'-dimethyl tyrosine-(Tyr-D-Arg-Phe-Lys-NH2) (abbreviated as DMT-DALDA; 10 pmol/h; μ agonist) or PZM21 (27 nmol/h; biased μ agonist). A second pump delivered subcutaneous naltrexone (25 µg/h) in some animals. After 14 to 16 days, animals were anesthetized and perfusion-fixed. Drug effects on degranulation of human cultured mast cells, mouse embryonic fibroblast activation/migration/collagen formation, and Mas-related G protein-coupled receptor activation (PRESTO-Tango assays) were determined. Intrathecal infusion of morphine, DMT-DALDA or PZM21, but not saline, comparably increased thermal thresholds for 7 days. Spinal masses proximal to catheter tip, composed of fibroblast/collagen type I (median: interquartile range, 0 to 4 scale), were produced by morphine (2.3: 2.0 to 3.5) and morphine plus naltrexone (2.5: 1.4 to 3.1), but not vehicle (1.2: 1.1 to 1.5), DMT-DALDA (1.0: 0.6 to 1.3), or PZM21 (0.5: 0.4 to 0.8). Morphine in a naloxone-insensitive fashion, but not PZM21 or DMT-DALDA, resulted in mast cell degranulation and fibroblast proliferation/collagen formation. Morphine-induced fibroblast proliferation, as mast cell degranulation, is blocked by cromolyn. Mas-related G protein-coupled receptor activation was produced by morphine and TAN67 (∂-opioid agonist), but not by PZM21, TRV130 (mu biased ligand), or DMT-DALDA. Opiates that activate Mas-related G protein-coupled receptor will degranulate mast cells, activate fibroblasts, and result in intrathecal mass formation. Results suggest a mechanistically rational path forward to safer intrathecal opioid therapeutics.

Sections du résumé

BACKGROUND
As the meningeally derived, fibroblast-rich, mass-produced by intrathecal morphine infusion is not produced by all opiates, but reduced by mast cell stabilizers, the authors hypothesized a role for meningeal mast cell/fibroblast activation. Using the guinea pig, the authors asked: (1) Are intrathecal morphine masses blocked by opiate antagonism?; (2) Do opioid agonists not producing mast cell degranulation or fibroblast activation produce masses?; and (3) Do masses covary with Mas-related G protein-coupled receptor signaling thought to mediate mast cell degranulation?
METHODS
In adult male guinea pigs (N = 66), lumbar intrathecal catheters connected to osmotic minipumps (14 days; 0.5 µl/h) were placed to deliver saline or equianalgesic concentrations of morphine sulfate (33 nmol/h), 2',6'-dimethyl tyrosine-(Tyr-D-Arg-Phe-Lys-NH2) (abbreviated as DMT-DALDA; 10 pmol/h; μ agonist) or PZM21 (27 nmol/h; biased μ agonist). A second pump delivered subcutaneous naltrexone (25 µg/h) in some animals. After 14 to 16 days, animals were anesthetized and perfusion-fixed. Drug effects on degranulation of human cultured mast cells, mouse embryonic fibroblast activation/migration/collagen formation, and Mas-related G protein-coupled receptor activation (PRESTO-Tango assays) were determined.
RESULTS
Intrathecal infusion of morphine, DMT-DALDA or PZM21, but not saline, comparably increased thermal thresholds for 7 days. Spinal masses proximal to catheter tip, composed of fibroblast/collagen type I (median: interquartile range, 0 to 4 scale), were produced by morphine (2.3: 2.0 to 3.5) and morphine plus naltrexone (2.5: 1.4 to 3.1), but not vehicle (1.2: 1.1 to 1.5), DMT-DALDA (1.0: 0.6 to 1.3), or PZM21 (0.5: 0.4 to 0.8). Morphine in a naloxone-insensitive fashion, but not PZM21 or DMT-DALDA, resulted in mast cell degranulation and fibroblast proliferation/collagen formation. Morphine-induced fibroblast proliferation, as mast cell degranulation, is blocked by cromolyn. Mas-related G protein-coupled receptor activation was produced by morphine and TAN67 (∂-opioid agonist), but not by PZM21, TRV130 (mu biased ligand), or DMT-DALDA.
CONCLUSIONS
Opiates that activate Mas-related G protein-coupled receptor will degranulate mast cells, activate fibroblasts, and result in intrathecal mass formation. Results suggest a mechanistically rational path forward to safer intrathecal opioid therapeutics.

Identifiants

pubmed: 31225809
doi: 10.1097/ALN.0000000000002730
pii: 00000542-201907000-00027
pmc: PMC6590697
mid: NIHMS1523857
doi:

Substances chimiques

Analgesics, Opioid 0
Receptors, G-Protein-Coupled 0
Morphine 76I7G6D29C

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

132-147

Subventions

Organisme : NIDA NIH HHS
ID : R01 DA015353
Pays : United States
Organisme : NINDS NIH HHS
ID : R01 NS102432
Pays : United States

Références

Acta Biomater. 2014 May;10(5):1856-63
pubmed: 24406200
Eur J Med Chem. 2000 Oct;35(10):895-901
pubmed: 11121615
Anesthesiology. 2003 Jul;99(1):174-87
pubmed: 12826858
Anesth Analg. 2005 Sep;101(3):728-34, table of contents
pubmed: 16115983
Br J Pharmacol. 2018 Jul;175(13):2653-2661
pubmed: 29582414
Curr Neuropharmacol. 2017;15(2):232-259
pubmed: 26861470
Neuromodulation. 2017 Feb;20(2):155-176
pubmed: 28042914
Pain Pract. 2018 Sep;18(7):889-894
pubmed: 29480977
J Pharmacol Exp Ther. 1989 Jul;250(1):1-8
pubmed: 2526212
Nucleic Acids Res. 1996 Feb 15;24(4):596-601
pubmed: 8604299
Int J Toxicol. 2018 Jan/Feb;37(1):4-27
pubmed: 29264927
Neuromodulation. 2013 Sep-Oct;16(5):459-66; discussion 466
pubmed: 23170763
Scand J Pain. 2019 Jan 28;19(1):193-206
pubmed: 30367811
Ann Surg. 1955 Dec;142(6):967-72
pubmed: 13269054
Biochem Biophys Res Commun. 2006 Nov 3;349(4):1322-8
pubmed: 16979137
Anesthesiology. 2012 Jan;116(1):170-81
pubmed: 22139590
Anesthesiology. 2016 Aug;125(2):378-94
pubmed: 27272672
Mayo Clin Proc. 1981 Aug;56(8):516-20
pubmed: 6894954
J Invest Dermatol. 2008 May;128(5):1298-310
pubmed: 17989729
Acta Neurochir (Wien). 2006 Aug;148(8):899-901; discussion 901
pubmed: 16791432
J Neurol Neurosurg Psychiatry. 1999 Aug;67(2):185-8
pubmed: 10406986
J Psychopharmacol. 2017 Jun;31(6):730-739
pubmed: 28142305
Pain. 1981 Dec;11(3):293-346
pubmed: 6276842
Nat Struct Mol Biol. 2015 May;22(5):362-9
pubmed: 25895059
PLoS One. 2014 Jan 22;9(1):e85226
pubmed: 24465509
Toxicol Appl Pharmacol. 2018 Jan 1;338:54-64
pubmed: 29111148
Anesthesiology. 2006 Sep;105(3):581-9
pubmed: 16931993
Histochemistry. 1986;85(1):41-9
pubmed: 3733471
J Pharmacol Exp Ther. 1989 Oct;251(1):216-23
pubmed: 2795458
J Neurol. 2009 Jan;256(1):66-71
pubmed: 19221848
Mol Pain. 2017 Jan-Dec;13:1744806917740030
pubmed: 29056067
Kidney Int. 1998 Feb;53(2):350-7
pubmed: 9461094
J Histochem Cytochem. 2014 Oct;62(10):751-8
pubmed: 25023614
Anesthesiology. 2013 Mar;118(3):664-78
pubmed: 23426209
Neurosurgery. 1991 Nov;29(5):778-84
pubmed: 1961414
Curr Protoc Immunol. 2010 Aug;Chapter 7:Unit 7.37
pubmed: 20814942
Brain Res. 1986 Oct 22;385(2):300-4
pubmed: 2877713
Leuk Res. 2003 Aug;27(8):677-82
pubmed: 12801524
J Neurosci Methods. 1997 Oct 3;76(2):183-91
pubmed: 9350970
Nature. 2016 Sep 8;537(7619):185-190
pubmed: 27533032
Immunology. 1989 Mar;66(3):434-8
pubmed: 2522909
Biochim Biophys Acta Gen Subj. 2017 Nov;1861(11 Pt A):2530-2534
pubmed: 28844982
Anesthesiology. 2006 Sep;105(3):590-8
pubmed: 16931994
Am J Physiol Lung Cell Mol Physiol. 2000 Jan;278(1):L193-201
pubmed: 10645907
Br J Pharmacol. 1970 Jan;38(1):253-62
pubmed: 4189829
Biomaterials. 2011 Nov;32(33):8394-403
pubmed: 21864899
Eur J Pharmacol. 2016 May 5;778:158-68
pubmed: 26130122
Anesthesiology. 2003 Jul;99(1):188-98
pubmed: 12826859
Pain Med. 2002 Dec;3(4):300-12
pubmed: 15099235
J Pharmacol Exp Ther. 2003 Dec;307(3):947-54
pubmed: 14534366
Nat Chem Biol. 2017 May;13(5):529-536
pubmed: 28288109
J Immunol. 1997 Mar 1;158(5):2310-7
pubmed: 9036979

Auteurs

Tony L Yaksh (TL)

From the Laboratory of Anesthesiology Research, Department of Anesthesiology (T.L.Y., K.A.E., S.K., R.R., Y.Z., Y.H., F.W., D.Q., S.A.M., J.J.S.) Department of Dermatology (Z.W., A.D.) Division of Trauma, Department of Surgery (B.P.E.), University of California, San Diego, California the Department of Pharmacology, University of North Carolina-Chapel Hill, Chapel Hill, North Carolina (K.L., W.K.K) Montreal Clinical Research Institute and the Department of Pharmacology and Physiology, University of Montreal, Quebec, Canada (P.W.S.) Department of Chemistry and Pharmacy, Friedrich-Alexander University Erlangen-Nurnberg, Erlangen, Germany (P.G.) Implantables Research and Technology, Medtronic, Inc., Restorative Therapies Group, Minneapolis, Minnesota (L.M.P., K.R.H.).

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH